Suppr超能文献

纤维肌痛综合征的药物治疗:基于实践的综述

Pharmacological Treatment of Fibromyalgia Syndrome: A Practice-Based Review.

作者信息

Giorgi Valeria, Sarzi-Puttini Piercarlo, Pellegrino Greta, Sirotti Silvia, Atzeni Fabiola, Alciati Alessandra, Torta Riccardo, Varrassi Giustino, Fornasari Diego, Coaccioli Stefano, Bongiovanni Sara Francesca

机构信息

Unità di Ricerca Clinica, Gruppo Ospedaliero Moncucco, Via Soldino, 5, 6900, Lugano, CH, Switzerland.

Rheumatology Unit, IRCCS Ospedale Galeazzi Sant'Ambrogio, Milan, Italy.

出版信息

Curr Pain Headache Rep. 2024 Dec;28(12):1349-1363. doi: 10.1007/s11916-024-01277-9. Epub 2024 Jul 23.

Abstract

PURPOSE OF REVIEW

Fibromyalgia Syndrome (FMS) is a complex chronic pain condition characterized by widespread musculoskeletal pain and numerous other debilitating symptoms. The purpose of this review is to provide a comprehensive overview, based on everyday clinical practice, of the drugs presently employed in the treatment of FMS.

RECENT FINDINGS

The treatment of FMS is based on a multimodal approach, with pharmacologic treatment being an essential pillar. The drugs used include tricyclic antidepressants, serotonin and noradrenaline reuptake inhibitors, other antidepressants, anticonvulsants, myorelaxants, and analgesics. The effectiveness of these medications varies, and the choice of drug often depends on the specific symptoms presented by the patient. Many drugs tend to either address only some domains of the complex FMS symptomatology or have a limited effect on pain. Each treatment option comes with potential side effects and risks that necessitate careful consideration. It may be beneficial to divide patients into clinical subpopulations, such as FMS with comorbid depression, for more effective treatment. Despite the complexities and challenges, the pharmacological treatment remains a crucial part for the management of FMS. This review aims to guide clinicians in prescribing pharmacological treatment to individuals with FMS.

摘要

综述目的

纤维肌痛综合征(FMS)是一种复杂的慢性疼痛病症,其特征为广泛的肌肉骨骼疼痛及众多其他使人衰弱的症状。本综述的目的是基于日常临床实践,全面概述目前用于治疗FMS的药物。

最新发现

FMS的治疗基于多模式方法,药物治疗是重要支柱。所使用的药物包括三环类抗抑郁药、5-羟色胺和去甲肾上腺素再摄取抑制剂、其他抗抑郁药、抗惊厥药、肌松药和镇痛药。这些药物的疗效各不相同,药物的选择通常取决于患者呈现的具体症状。许多药物往往仅能解决复杂的FMS症状学的某些方面,或对疼痛的影响有限。每种治疗方案都有潜在的副作用和风险,需要仔细考虑。将患者分为临床亚组,如伴有共病抑郁的FMS,可能有助于更有效的治疗。尽管存在复杂性和挑战,但药物治疗仍是FMS管理的关键部分。本综述旨在指导临床医生为FMS患者开具药物治疗处方。

相似文献

1
Pharmacological Treatment of Fibromyalgia Syndrome: A Practice-Based Review.
Curr Pain Headache Rep. 2024 Dec;28(12):1349-1363. doi: 10.1007/s11916-024-01277-9. Epub 2024 Jul 23.
2
The role of antidepressants in the management of fibromyalgia syndrome: a systematic review and meta-analysis.
CNS Drugs. 2012 Apr 1;26(4):297-307. doi: 10.2165/11598970-000000000-00000.
3
Pharmaceutical treatment options for fibromyalgia.
Curr Rheumatol Rep. 2004 Aug;6(4):274-80. doi: 10.1007/s11926-004-0035-y.
4
Pharmacological treatment of fibromyalgia.
Clin Exp Rheumatol. 2010 Nov-Dec;28(6 Suppl 63):S110-6. Epub 2010 Dec 22.
5
Available therapies and current management of fibromyalgia: focusing on pharmacological agents.
Drugs Today (Barc). 2011 Jul;47(7):539-57. doi: 10.1358/dot.2011.47.7.1603503.
6
Pharmacological treatment of fibromyalgia and other chronic musculoskeletal pain.
Best Pract Res Clin Rheumatol. 2007 Jun;21(3):499-511. doi: 10.1016/j.berh.2007.02.012.
8
Emerging therapies for fibromyalgia.
Expert Opin Emerg Drugs. 2008 Mar;13(1):53-62. doi: 10.1517/14728214.13.1.53.
9
Present state of medication therapy in fibromyalgia syndrome.
Scand J Rheumatol Suppl. 2000;113:32-6. doi: 10.1080/030097400446616.
10
The neuropharmacology of centrally-acting analgesic medications in fibromyalgia.
Rheum Dis Clin North Am. 2002 May;28(2):235-59. doi: 10.1016/s0889-857x(01)00004-7.

引用本文的文献

2
Exploiting allosteric modulation: a new frontier for precision medicine.
Mol Biol Rep. 2025 Jun 4;52(1):549. doi: 10.1007/s11033-025-10650-9.
5
A Comprehensive Analysis of Fibromyalgia and the Role of the Endogenous Opioid System.
Biomedicines. 2025 Jan 11;13(1):165. doi: 10.3390/biomedicines13010165.
6
Exploring Chronic Pain in Hemodialysis Patients: An Observational Study Based on the New IASP Classification for ICD-11.
Pain Ther. 2025 Feb;14(1):375-385. doi: 10.1007/s40122-024-00698-z. Epub 2025 Jan 4.
7
Pain Management in Fibromyalgia: Evaluating the Roles of Pregabalin, Duloxetine, and Milnacipran.
Cureus. 2024 Dec 30;16(12):e76631. doi: 10.7759/cureus.76631. eCollection 2024 Dec.

本文引用的文献

1
Outpatient Ketamine Infusions for the Treatment of Fibromyalgia and Chronic Pain Syndrome: A Case Report.
Cureus. 2023 Sep 8;15(9):e44909. doi: 10.7759/cureus.44909. eCollection 2023 Sep.
3
Long-term opioid treatment and endocrine measures in chronic non-cancer pain patients.
Eur J Pain. 2023 Sep;27(8):940-951. doi: 10.1002/ejp.2136. Epub 2023 May 26.
4
Effectiveness of Hyperbaric Oxygen for Fibromyalgia: A Meta-Analysis of Randomized Controlled Trials.
Clin Pract. 2023 Apr 26;13(3):583-595. doi: 10.3390/clinpract13030053.
6
Tapentadol: A Review of Experimental Pharmacology Studies, Clinical Trials, and Recent Findings.
Drug Des Devel Ther. 2023 Mar 21;17:851-861. doi: 10.2147/DDDT.S402362. eCollection 2023.
7
Fibromyalgia patients with elevated levels of anti-satellite glia cell immunoglobulin G antibodies present with more severe symptoms.
Pain. 2023 Aug 1;164(8):1828-1840. doi: 10.1097/j.pain.0000000000002881. Epub 2023 Mar 22.
8
Fibromyalgia predicts increased odds of pain-related addiction exacerbation among individuals with pain and opioid use disorder.
Pain. 2023 Aug 1;164(8):1801-1809. doi: 10.1097/j.pain.0000000000002878. Epub 2023 Mar 14.
9
Predictors of treatment response to serotonin and noradrenaline reuptake inhibitors in fibromyalgia.
Pol Arch Intern Med. 2023 Aug 30;133(7-8). doi: 10.20452/pamw.16432. Epub 2023 Feb 14.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验